Drug Trial Radar · NCT06968845
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Rein TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (scarring) of the lungs. As the disease progresses, patients experience loss of lung function and increased breathing problems. LTI-03 is hypothesized to treat IPF by protecting and restoring the function of the oxygen uptake cells and by controlling lung fibrosis which may result in improving lung scarring. The purpose of this research is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate. Trial Design: This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study that includes a 28-day Screening Period, a 24-week Treatment Period, and 4-week Follow-up Period. Study Assessments: Up to 9 visits to the study clinic will be required. Safety and tolerability will be evaluated with the following assessments: physical examination; collection of vital sign data (heart rate, blood pressure, respiratory rate and peripheral oxygen saturation \[SpO2\] via pulse oximetry); heart data collected by 12-lead electrocardiogram; and collection of blood samples for safety laboratory tests. In addition, participants will be asked about any adverse events (side effects) they have experienced between clinic visits, if they have changed any medications, and if they are able to properly use their study drug inhaler. Participants will undergo a lung function test (spirometry) at every visit, which will be used to evaluate both safety and efficacy. Another test measuring the diffusion capacity of the lungs for carbon monoxide (DLCO) will be required at Screening only. Blood samples will also be collected at each visit to measure disease biomarkers. At select visits patients will be asked to complete the Living with Pulmonary Fibrosis questionnaire to evaluate their IPF symptoms. Participants will also undergo a specialized lung scan (HRCT) at Baseline and at the End of Treatment to measure changes in lung fibrosis. Interventions: LTI-03 and placebo are provided in powder-filled capsules that participants will self- administer using an inhaler. Placebo capsules look like LTI-03 capsules but have no active ingredients. Approximately 120 participants will be randomly assigned in a blinded manner to one of study drug treatment groups.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
LTI-03Drug
Caveolin-1-Scaffolding-Protein-Derived Peptide
Dry Powder InhalerDevice
Plastiape Monodose RS01 Model 7
PlaceboDrug
Lactose powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs)Time frame: Day 1 through Week 24
Locations
48 sites in 7 countries. Site status is shown where the registry gives one.
UAB Lung Health Center
Birmingham, Alabama · Recruiting
University of Southern California
Los Angeles, California · Recruiting
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
Paradigm Clinical Research Centers, LLC
San Diego, California · Recruiting
National Jewish Health
Denver, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Cleveland Clinic Florida
Weston, Florida · Recruiting
Indiana University
Indianapolis, Indiana · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
The Lung Research Center, LLC
Chesterfield, Missouri · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Atrium Health Wake Forest School of Medicine
Winston-Salem, North Carolina · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
El Paso Pulmonary Association
El Paso, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Baylor Scott and White Health
Temple, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Launceston Respiratory and Sleep Centre
Launceston, Tasmania, Australia · Recruiting
Box Hill Hospital
Box Hill, Victoria, Australia · Recruiting
Lung Research Victoria
Melbourne, Victoria, Australia · Recruiting
MCpulmo-2018 Ltd
Haskovo, Bulgaria · Recruiting
Diagnostic- Consultative Center Convex EOOD
Sofia, Bulgaria · Recruiting
Diagnostic- Consultative Center Convex EOOD
Sofia, Bulgaria · Recruiting
Thoraxklinik-Heidelberg gGmbH Studienzentrum ThoraxKliPS
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Agaplesion Evangelisches Krankenhaus Mittelhessen
Giessen, Hesse, Germany · Recruiting
Medical University of Łódź
Lodz, Łódź Voivodeship, Poland · Recruiting
Prywatny Gabinet Lekarski Ginekologia i Poloznictwo Ultrasonografia Prof. Jacek Suzin
Lodz, Lódzkie, Poland · Recruiting
Twoja Przychodnia NCM
Nowa Sól, Lubusz Voivodeship, Poland · Recruiting
EMed Centrum Uslug Medycznych
Rzeszów, Podkarpackie Voivodeship, Poland · Recruiting
Instytut Gruzlicy i Chrob Pluc
Warsaw, Poland, Poland · Recruiting
Salus Aegroti Praktyka Lekarska dr n. med. Grzegorz Gąsior
Sosnowiec, Silesian Voivodeship, Poland · Recruiting
FutureMeds Bucharest - PPDS
Bucharest, Romania · Recruiting
Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova
Craiova, Romania · Recruiting
AI Clinical Research
Sibiu, Romania · Not yet recruiting
Sf. Ioan cel Nou Emergency County Hospital
Suceava, Romania · Not yet recruiting
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.